People locomotion by electrical motortruck shaper Rivian's recently opened storefront successful the Meatpacking District of Manhattan connected June 23, 2023 successful New York City.
Spencer Platt | Getty Images
Check retired the companies making headlines successful midday trading.
Electric vehicles — Electric conveyance makers specified arsenic Rivian Automotive surged pursuing Tesla's better-than-expected second-quarter accumulation and transportation numbers. Rivian jumped 17.4%, Fisker roseate 1.4% and Lucid Group precocious 7%.
XPeng — The U.S.-listed shares of XPeng climbed 4%. The Chinese electrical conveyance shaper returned to maturation for car deliveries. In the 2nd quarter, it delivered 23,205 vehicles, a 27% quarter-over-quarter increase.
Tesla — Shares of the the Elon Musk-led electrical conveyance institution jumped 6.9% aft delivery and production numbers beat analysts' expectations. The 2nd 4th of 2023 marked the 5th successful a enactment erstwhile Tesla reported a higher level of vehicles produced compared with deliveries.
Chinese net stocks — China-based exertion names roseate connected Monday. The KraneShares CSI China Internet ETF added 2.3%, lifted by shares of Alibaba, higher by astir 0.9%, and Pinduoduo, up 3.1%. Shares of JD.com gained astir 3%.
Solar stocks — Solar stocks SolarEdge Technologies and Enphase Energy roseate 0.5% and 1.2%, respectively, connected Monday.
Semiconductors — Semiconductor names roseate connected Monday. Shares of Marvell Technology and Micron Technology were each higher by 2.6% and astir 1.3%, respectively.
Apple — Apple declined 0.5% aft the Financial Times, citing radical with nonstop cognition of the matter, reported the iPhone shaper was forced to chopped accumulation forecasts for its Vision Pro headset. Apple shares closed above a $3 trillion marketplace worth connected Friday.
AstraZeneca — Shares sank 8% aft the Cambridge, England-based drugmaker announced disappointing preliminary results for a signifier 3 proceedings of a lung crab treatment. AstraZeneca said it slowed progression of the cancer, but the information for wide endurance was "not mature" and the results were not statistically significant. The proceedings volition proceed to measure wide endurance with greater maturity, the institution said.
— CNBC's Michelle Fox and Yun Li contributed reporting
English (US) ·